Advancing Gene Therapy for Late Infantile Neuronal Ceroid Lipofuscinosis

描述（由申请方提供）：晚期婴儿神经元蜡样脂褐质沉积症（LINCL）是一种儿童期发病的常染色体隐性遗传神经退行性疾病。这种疾病是一种溶酶体贮积病（LSD），由编码溶酶体水解酶三肽基肽酶I（TPP 1）的基因CLN 2突变引起。TPP 1缺乏导致癫痫发作、视力障碍、认知和运动功能障碍，并且在儿童晚期总是致命的。目前，没有治疗或治愈这种毁灭性疾病的方法。治疗的主要障碍是将生物活性TPP 1酶递送至中枢神经系统，这一目标受到血脑屏障（BBB）的选择性的阻碍。在最近的研究中，我们的实验室已经设计了脑归巢腺相关病毒（AAV）基因递送载体。脑嗜性的病毒是由肽，GMNAFRA，我们确定了体内噬菌体展示淘选在小鼠模式LINCL。GMN肽对脑血管内皮细胞的腔表面具有亲和力，脑血管内皮细胞是BBB的主要成分。当外周递送时，这种肽修饰的病毒（GMN-AAV）行进到脑内皮并转导脑内皮。值得注意的是，在LINCL小鼠中递送编码CLN 2的GMN-AAV恢复了脑中的TPP 1表达并纠正了神经病理学缺陷。因此，这种新的基因治疗方法通过工程化内皮细胞将重组酶直接分泌到潜在的神经元中来绕过BBB。为了推进这种令人兴奋的和有前途的基因治疗方法LINCL患者，阐明与GMN肽相互作用的脑内皮受体分子的身份是必要的。该提案的总体目标是进行实验以发现介导GMN-AAV脑靶向和转导的这种分子。我们的假设是，该受体是一个质膜相关蛋白或聚糖部分表达的脑血管内皮细胞表面上的TPP 1缺陷的大脑。目的一：利用亲和纯化和定量质谱的方法分离鉴定GMN-AAV受体。在目标二中，我们将使用由NIH运营的功能糖组学联盟开发的哺乳动物聚糖阵列来确定GMN-AAV是否与可能存在于脑内皮细胞表面上的特定聚糖或聚糖类别结合。这些目标的实现将使我们能够推进这一翻译工作。 新的基因治疗LINCL儿童。此外，这种治疗策略可以广泛应用于其他导致中枢神经系统功能障碍和神经退行性变的LSD。

DESCRIPTION (provided by applicant): Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is a childhood-onset autosomal recessive neurodegenerative disease. This disorder, a lysosomal storage disease (LSD), is caused by mutations in CLN2, the gene that encodes the lysosomal hydrolase tripeptidyl peptidase I (TPP1). TPP1 deficiency causes epileptic seizures, vision impairment, cognitive and motor dysfunction, and is invariably fatal by late childhood. Currently, there is no treatment or cure for this devastating disease. The major barrier to treatment is the delivery of bioactive TPP1 enzyme to the central nervous system, a goal hindered by the selectivity of the blood-brain-barrier (BBB). In recent studies, our lab has engineered a brain-homing adeno-associated virus (AAV) gene delivery vector. Brain tropism of the virus is conferred by a peptide, GMNAFRA, which we identified by in vivo phage display panning in a mouse mode of LINCL. The GMN peptide has affinity for the luminal surface of brain vascular endothelial cells, which are the primary component of the BBB. When delivered peripherally, this peptide-modified virus (GMN-AAV) travels to, and transduces brain endothelia. Significantly, delivery of GMN-AAV encoding CLN2 in LINCL mice restored TPP1 expression in the brain and corrected neuropathological defects. Thus, this novel gene therapy approach bypasses the BBB by engineering endothelial cells to secrete recombinant enzyme directly into the underlying neuropil. In order to advance this exciting and promising gene therapy approach to LINCL patients, elucidation of the identity of the brain endothelial receptor molecule that interacts with the GMN peptide is required. The overall goal of this proposal is to perform experiments to discover this molecule, which mediates GMN-AAV brain targeting and transduction. Our hypothesis is that the receptor is a plasma membrane-associated protein or glycan moiety expressed on the surface of brain vascular endothelial cells in TPP1 deficient brain. In aim one, we will use affinity purification and quantitative mass spectrometry methods to isolate and identify the GMN-AAV receptor. In aim two, we will use a mammalian glycan array developed by the NIH-operated Consortium for Functional Glycomics to determine whether GMN-AAV binds to specific glycans or classes of glycans that may be present on the surface of brain endothelial cells. Completion of these aims will enable us to advance the translation of this novel gene therapy to children with LINCL. In addition, this therapeutic strategy could be broadly applied to other LSDs that cause central nervous system dysfunction and neurodegeneration.